Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

984
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
984
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.5K
Structure and Function of Platelets01:18

Structure and Function of Platelets

2.7K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.7K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

157
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
157
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

187
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
187

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age-related symptom clustering in pediatric hypermobility spectrum disorders: a scoping review.

Orphanet journal of rare diseases·2026
Same author

Preterm Birth Increases Susceptibility to Hyperglycemia-Induced Kidney Injury With Sex-Specific Differences in Structural and Molecular Responses.

Endocrinology, diabetes & metabolism·2026
Same author

Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial.

The Lancet. Infectious diseases·2026
Same author

Health Care-Associated Infections Among Neonates During the COVID-19 Pandemic.

JAMA network open·2026
Same author

Regadenoson in the rehabilitation of marginal donor lungs on ex vivo lung perfusion: A blinded multicenter randomized controlled clinical trial.

JTCVS open·2025
Same author

Characteristics and outcomes of adult emergency ward patients with sepsis who received corticosteroids at the Mbarara Regional Referral Hospital in Uganda.

Emergency medicine journal : EMJ·2025

Related Experiment Video

Updated: Dec 29, 2025

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.4K

Picking up the Pace: Decreasing Platelet Administration Safely and Effectively.

Susan Steck1, Elizabeth Miller-Davis1, Mark Conaway2

  • 1University of Virginia Medical Center, Charlottesville, VA, USA.

Journal of Pediatric Nursing
|February 5, 2020
PubMed
Summary
This summary is machine-generated.

Administering platelets (PLTs) over 30-45 minutes is safe and effective for pediatric hematology-oncology patients. This shorter transfusion time allows for quicker patient recovery and disconnection from IV pumps.

Keywords:
Hematology-oncologyPlateletPlatelet administration

More Related Videos

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.4K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.1K

Related Experiment Videos

Last Updated: Dec 29, 2025

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.4K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.4K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.1K

Area of Science:

  • Pediatric Hematology-Oncology
  • Transfusion Medicine
  • Clinical Nursing

Background:

  • Hematology-oncology patients frequently require platelet (PLT) transfusions for stability.
  • Shorter transfusion times may increase PLT counts faster and reduce IV pump duration.

Purpose of the Study:

  • To compare the safety and efficacy of standard (2-4 hour) versus investigational (30-45 minute) PLT transfusion times.
  • To evaluate optimal transfusion duration in pediatric hematology-oncology inpatients.

Main Methods:

  • A pilot randomized trial involving pediatric hematology-oncology patients receiving PLT transfusions.
  • Patients were assigned to either a 30-45 minute or a 2-4 hour transfusion group.
  • Post-transfusion PLT counts were assessed 30 minutes after completion, with close monitoring for adverse events.

Main Results:

  • Eleven participants completed the study with 20 PLT infusions administered.
  • No adverse events were observed in either transfusion group.
  • While no significant difference was found in overall PLT count changes or post-infusion counts, the rate of PLT count change differed significantly between groups (p=0.003).

Conclusions:

  • Preliminary evidence suggests that PLTs can be safely and effectively transfused over 30-45 minutes in pediatric hematology-oncology patients.
  • Shorter transfusion durations may allow patients to be disconnected from IV pumps sooner, potentially improving patient comfort and resource utilization.